This sub-industry focuses on treatments that use living cells to repair or replace damaged tissue. 2024 sees increased investment and research in CAR-T cell therapies for cancer treatment.
Cautious investment is suggested. There may be selective opportunities for turnaround specialists or those with high risk tolerance.